Small Interfering RNA (siRNA) Inhibitor

Revusiran (ALN-TTRSC) sodium is an RNA interference agent targeting the mRNA of transthyretin (Transthyretin, TTR). Revusiran sodium mediates sequence-specific degradation of TTR mRNA through RNA interference, reduces the synthesis of TTR protein, binds to GalNAc ligands, and is taken up by hepatocytes via the asialoglycoprotein receptor. Revusiran sodium exhibits favorable nonclinical safety profiles. Revusiran sodium can be used in studies related to transthyretin-mediated amyloidosis.

Olpasiran (AMG 890, ARC-LPA) sodium is an N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted siRNA. Olpasiran sodium directly inhibits LPA messenger RNA translation in hepatocytes and potently reduce Lp(a) concentration. Olpasiran sodium can be used for the research of cardiovascular disease, such as atherosclerosis.

Adenosine-3',5'-bisphosphate ammonium is a XRN1 inhibitor (IC₅₀ = 36 nM). Adenosine-3',5'-bisphosphate ammonium can be used in the study of colorectal cancer, breast cancer and lung cancer.

PF-04523655 sodium is a siRNA directed against RTP801 gene. RTP801 sodium is an inhibitor of the mammalian target of rampamycin complex 1 (mTORC1) and downstream transcription factor HIF-1.

ATU027 sodium is a siRNA, which silences expression of protein kinase N3 (PKN3) in the vascular endothelium. ATU027 sodium has previously been shown to inhibit local tumor invasion as well as lymph node and pulmonary metastasis in mouse cancer models.

PF-04523655 sodium scrambled negative control is the sequence scrambled negative control of PF-04523655 sodium.

Zerlasiran (SLN360) sodium scrambled negative control is the sequence scrambled negative control of Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.

Elebsiran (VIR-2218) is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran can be used for the study of chronic HBV/HDV infections.

Manusiran sodium scrambled negative control is the sequence scrambled negative control of Manusiran sodium.

ATU027 sodium scrambled negative control is the sequence scrambled negative control of ATU027 sodium.

Revusiran sodium scrambled negative control is the sequence scrambled negative control of Revusiran sodium.

Bamosiran sodium is a small interfering RNA targeting β-adrenergic receptor 2, and is used to lower intraocular pressure

Adenosine-3',5'-bisphosphate is an exoribonuclease XRN1 inhibitor with an IC₅₀ of 36 nM, a K_D of 12 nM, and a K_D of 14 nM against human XRN2. Adenosine-3',5'-bisphosphate binds to the bimetallic active site of human XRN1, and also binds potently to human XRN2 via its conserved bimetallic active site. Adenosine-3',5'-bisphosphate can be used in research related to non-small cell lung cancer.

Olpasiran sodium scrambled negative control is the sequence scrambled negative control of Olpasiran sodium.

HDAC/PSMD14-IN-1 (Compound 8B) is a thiolutin derivative. HDAC/PSMD14-IN-1 is a orally active dual-target inhibitor of PSMD14/HDAC1 (IC₅₀ 238.7 nM/141.2 nM, respectively). HDAC/PSMD14-IN-1 has good cytotoxicity against ESCC cell lines (IC₅₀: 30-250 nM) and effectively reverses epithelial-mesenchymal transition (EMT). HDAC/PSMD14-IN-1 can induce apoptosis. HDAC/PSMD14-IN-1 has anti-tumor activity in a KYSE30 cell mouse xenograft model. HDAC/PSMD14-IN-1 can be used in anti-esophageal cancer research.

CeMMEC1 (hydrochloride) is an N-methylisoquinolinone derivative that inhibit the second bromodomain of TAF1 with an IC₅₀ of 0.9 μM.

Bamosiran sodium scrambled negative control is the sequence scrambled negative control of Bamosiran sodium.